VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant ...

VERAXA Biotech is implementing FDA-aligned New Approach Methodologies (NAMs) in its preclinical R&D to accelerate clinical trials and reduce animal testing, especially in cancer antibody therapies. This strategy uses human-relevant models like organ-on-chip and ex vivo patient-derived xenografts to improve drug development efficiency and sustainability.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.